For millions of Americans with type 2 diabetes, Ozempic is a game-changer. But at over $900 a month without insurance, it's also a financial gut punch. Meanwhile, just a few hours north, Canadians are now buying generic versions for a fraction of the price. The reason isn't magic—it's a clash of patents, politics, and pricing power that reveals a lot about how drug costs work on both sides of the border.
A tale of two markets
Canada's health system doesn't directly control drug prices, but its Patented Medicine Prices Review Board does set maximums. When Novo Nordisk's patent on semaglutide (the active ingredient in Ozempic) expired in Canada last year, generic manufacturers jumped in. The result? A 60-day supply of generic semaglutide now runs about $150 CAD—roughly $110 USD. In the U.S., the same branded Ozempic can cost $1,200 or more.
The key difference: the U.S. allows drug companies to keep competitors off the market through 'patent thickets'—layers of secondary patents on delivery devices, dosing regimens, and manufacturing processes. Canada's patent office is stricter about what counts as a true innovation, so generics can launch sooner.
Why Americans pay more
The U.S. is the only developed country that doesn't let the government negotiate drug prices for Medicare. That means drugmakers can set sky-high prices, and middlemen like pharmacy benefit managers often take a cut. Even when generics do enter the U.S. market—like for metformin or insulin—they often cost more than in Canada because of fragmented distribution and lack of price controls.
There's also the issue of 'reverse payment' deals, where brand-name companies pay generics to delay launching cheaper versions. The U.S. Federal Trade Commission has challenged some of these, but they remain common. In Canada, such deals are harder to enforce because of different antitrust rules.
What this means for patients
For now, Americans can't legally buy Canadian generics. The FDA restricts importation, and most online pharmacies that claim to sell 'Canadian' drugs actually ship from India or other countries with less oversight. Some states are exploring bulk importation from Canada, but legal challenges from the pharmaceutical industry have stalled those efforts.
The bottom line? If you're Canadian, you're saving hundreds a month. If you're American, you're stuck waiting for patent cliffs—or hoping Congress finally allows Medicare to negotiate prices. Either way, the Ozempic story is a clear snapshot of why drug costs are so different just a few hundred miles apart.